医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Alvogen Subsidiary Confirms ANDA Filing and Patent Challenge for Generic Revlimid®

2017年09月11日 PM07:54
このエントリーをはてなブックマークに追加


 

PINE BROOK, N.J.

Alvogen subsidiary, Lotus Pharmaceuticals (“Lotus”), today announced that Celgene filed a suit on 6 September 2017 in the United States District Court for the District of New Jersey. The lawsuit was filed under provisions of the Hatch-Waxman Act, resulting in a stay of final Food and Drug Administration (FDA) approval of Lotus’ Abbreviated New Drug Application (ANDA) for up to 30 months from the date the plaintiffs, Celgene, received notice of Lotus’ ANDA filing or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170911005513/en/

Robert Wessman Chairman and CEO (Photo: Business Wire)

Robert Wessman Chairman and CEO (Photo: Business Wire)

Lotus filed an ANDA with the United States FDA seeking regulatory approval to market a generic version of Revlimid®. Lotus’ ANDA included a paragraph IV certification with respect to the patents listed in the FDA’s listing of Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”).

Lotus’ ANDA product is a generic version of Celgene’s Revlimid® 2.5, 5, 10, 15, 20 and 25 mg, which is indicated for the treatment of several hematological malignancies including multiple myeloma. The product was developed by Lotus pharmaceuticals in Taiwan.

Robert Wessman, Alvogen Chairman and CEO, said, “The FDA acceptance of our ANDA filing is an important milestone for our U.S. business and great news for patients, who will finally have access to a more affordable treatment. I would like to thank our teams in the U.S. and Taiwan for their valuable efforts in submitting this filing.”

Revlimid® is a trademark of Celgene Corporation.

Alvogen currently has 75 products in development and pending FDA approvals for the U.S. market. Annual brand sales for filed products and those under development exceeds $25 billion, according to IMS Health (2015).

About Alvogen

Alvogen is a global, privately owned pharmaceutical company focused on developing, manufacturing and selling generic, brand, over-the-counter brands (OTC) and biosimilar products for patients around the world. The company has commercial operations in 35 countries with 2,800 employees and operates four manufacturing and development hubs in the US, Romania, Korea and Taiwan. North America is Alvogen’s single largest market and other key markets include: South Korea, Russia, Hungary, Romania, Taiwan, Ukraine, Japan and China.

A consortium of investors, led by CVC Capital Partners and including Singapore-based investment company Temasek and Vatera Healthcare Partners, acquired a majority stake in Alvogen in June 2015.

Visit www.alvogen.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20170911005513/en/

CONTACT

Alvogen
Halldor Kristmannsson, (+354) 522-2900
Global
Corporate Marketing & Media Relations
halldor@alvogen.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • ノクソファームが敗血症性ショック治療の効用でビヨンダの特許を出願
  • 东阳光药选择ABEC大型发酵罐以提高生物制药生产能力
  • Aural Analytics, Inc. and Healint, Pte. Ltd. Partner on Integration of Speech Analytics into Healint’s Suite of Clinical Trials and Widely Used Consumer Applications
  • Anji Pharma Adds Clinical Sites to Accelerate Clinical Development of Pradigastat for the Treatment of Functional Constipation
  • ROSALIND, HELiXrUS and Geninus Partner to Bring Powerful New Single Cell Analysis Services to Cancer Researchers